at 1 millimeter less than the perimeter-derived diameter,” Boston Scientific’s chief medical officer for interventional cardiology therapies, Janar Sathananthan, M.D., said in an interview.
This is a strategic move poised to significantly expand the company’s cardiology portfolio. By paying $27.50 per share, Boston Scientific is offering a 38% premium over Silk Road's volume ...
Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional ... segment consists of Cardiology and Peripheral Interventions.
Boston Scientific reported 29.2% growth for cardiology products and 11.8% growth in peripheral interventions. MedSurg segment revenues increased 10.3% to $1.48 billion (10.4% operationally and 7.7 ...